Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, July 15, 2025 (HealthDay News) — For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published online July 9 in Diabetes, Obesity and Metabolism<\/em>.<\/p>\n Jingxuan Wang, M.D., from Peking University People’s Hospital in Beijing, and colleagues conducted a retrospective cohort study to characterize weight fluctuation and influencing factors after GLP-1 RA treatment. The analysis included 679 adult patients with overweight or obesity initiating GLP-1 RA treatment between November 2022 and October 2024.<\/p>\n The researchers found that patients with a longer duration of GLP-1 RA treatment (odds ratio [OR],\u20091.014) and higher Homeostasis Model Assessment of \u03b2-Cell Function levels (OR,\u20094.912) were more likely to achieve successful weight reduction at 12-month follow-up. At six months of follow-up, nondiabetic status (OR,\u20092.176) and using semaglutide (OR,\u20092.138) were associated with successful weight reduction. In both male and female participants, a higher percentage body fat was associated with successful weight reduction (ORs,\u20093.990 and 2.266, respectively). Those with weight regain had a higher baseline estimated glomerular filtration rate at the three-month follow-up, especially for participants with prediabetes. There were J-shaped associations for basal metabolic rate, skeletal muscle mass, and abdominal and limb muscle mass with the probability of successful weight reduction within six\u2009months. There was a positive nonlinear association for serum creatinine with the probability of successful weight reduction within 12\u2009months.<\/p>\n “These findings may provide novel insights into the weight fluctuations after GLP-1 RA treatment in the real-world setting, thereby advancing the development of individualized strategies with GLP-1 RA therapy for patients with overweight or obesity,” coauthor Linong Ji, M.D., also from Peking University People’s Hospital, said in a statement.<\/p>\n One author disclosed ties to industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n